title: [Evoluting form of cancrum oris, about 55 cases collected at the Academic Hospital Yalgado Ouedraogo of Ouagadougou].
abstract: The cancrum oris is still an up to date disease in our environment. The death rate and the after effects of this disease make all together the main interest of this survey. In a retrospective survey carried out from January 2003 to December 2012, we colligated 55 cases of progressive cancrum oris followed at the stomatological and maxillofacial surgery at the Academic Hospital Yalgado OUEDRAOGO. On the epidemiological level, we noticed an impact of 5.5 cases per year. The average age of our patients was about 7.64 with a sex ratio of 1.03. Most of the patients were from an underprivileged family (96.4%). On the clinical level, we noticed that most of the patients consulted only after the gangrene had fallen (89.1%) and were seriously affected (67.3%) with a bad oral and dental hygiene (38.1%). The attacks were mainly jugal (25%) and labial (24.1%). The cancrum oris was in most of the cases associated to broncho pneumonitis, malaria and to HIV infection (31.37%). For the medical treatment, we focused on resuscitation, re nutrition, hydro electrolytic rebalancing and antibiotherapy. The surgical treatment was essentially made on the affected areas, controlled skinning and most often followed by sequestrectomy. 81.8% of the patients recovered completely from the infection, 60% had after effect injuries. We recorded a death rate of 14.5%. In order to overcome this disease we need both national and international support.
authors.affiliation: Service de stomatologie et chirurgie maxillo-faciale du CHU Yalgado Ouedraogo, Ouagadougou, Burkina Faso.
authors.forename: T
authors.initials: T
authors.lastname: Konsem
authors.forename: M
authors.initials: M
authors.lastname: Millogo
authors.forename: C
authors.initials: C
authors.lastname: Assouan
authors.forename: D
authors.initials: D
authors.lastname: Ouedraogo
mesh_terms: D000293:Adolescent; D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use; D001996:Bronchopneumonia / Q000453:epidemiology; D002050:Burkina Faso / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D015897:Comorbidity; D003646:Debridement; D018450:Disease Progression; D005148:Facial Dermatoses / Q000209:etiology / Q000601:surgery / Q000628:therapy; D005260:Female; D015658:HIV Infections / Q000453:epidemiology; D006784:Hospitals, Teaching / Q000706:statistics & numerical data; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D008288:Malaria / Q000453:epidemiology; D008297:Male; D044342:Malnutrition / Q000453:epidemiology; D008875:Middle Aged; D009625:Noma / Q000453:epidemiology* / Q000382:microbiology / Q000473:pathology / Q000628:therapy; D011203:Poverty; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome; D014883:Water-Electrolyte Imbalance / Q000453:epidemiology / Q000628:therapy; D055815:Young Adult
chemical_list: D000890:Anti-Infective Agents